Akari Therapeutics (AKTX)
NASDAQ:AKTX
Want to see AKTX full AI Analyst Report?
AKTX Stock Chart & Stats
$0.28
-$0.09(-6.73%)
At close: 4:00 PM EST
$0.28
-$0.09(-6.73%)
Day’s Range― - ―
52-Week Range$3.02 - $49.60
Previous CloseN/A
Volume16.29K
Average Volume (3M)1.63M
Market Cap
$12.85M
Enterprise Value$11.70M
Total Cash (Recent Filing)$2.77M
Total Debt (Recent Filing)$732.00K
Price to Earnings (P/E)―
Beta1.41
Next Earnings
May 20, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1448.00
Shares Outstanding1,144,588
10 Day Avg. Volume2,851,768
30 Day Avg. Volume1,628,756
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$27.00Price Target Upside9542.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.89
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageThe company’s minimal debt load is a durable structural strength: low leverage reduces near-term refinancing risk and interest burden, preserving optionality to fund clinical programs through equity or partnerships. This conserves cash flexibility over the next several quarters.
Focused R&D PipelineA concentrated therapeutic focus builds specialized scientific expertise and program depth, improving chances of clinical progress or strategic partnerships. Over months this improves R&D efficiency and makes the company an attractive collaborator or acquisition target in its niche.
Committed Near-term FinancingSecuring a structured private placement extends operational runway and reduces immediate cash stress, enabling continued clinical and regulatory activities. While dilutive, committed tranches and pre-funded warrants materially lower the probability of an imminent funding shortfall.
Bears Say
No Revenue / Persistent LossesA pre-commercial biotech model with sustained large operating losses is a long-term structural weakness: without product revenue the firm must rely on external funding or partnerships. Persistent losses erode resources and make long-term viability contingent on successful trials or continued financings.
Negative Free Cash FlowOngoing negative free cash flow is a durable constraint: recurring cash burn requires repeated capital raises, which dilute shareholders and can limit investment pacing. Even with improved burn versus earlier years, continued negative FCF raises execution and financing risk over the next 2-6 months.
Eroding Equity BaseMaterial decline in shareholders' equity reduces the balance-sheet buffer against further losses and heightens reliance on external capital. This structural weakening increases vulnerability to dilution and constrains strategic flexibility for partnerships or M&A over the medium term.
Akari Therapeutics News
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $3.02 and its highest was $49.60 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $12.85M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is May 20, 2027 which is in 330 days.
How were Akari Therapeutics’s earnings last quarter?
Currently, no data Available
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 1,144,588 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akari Therapeutics
Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nomacopan holds promise for a range of serious conditions, including paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). Akari's operations are headquartered in London, United Kingdom.
AKTX Stock 12 Month Forecast
Average Price Target
$27.00
▲(9542.86% Upside)
Technical Analysis
Ownership Overview
25.66% Insiders
7.32% Other Institutional Investors
67.02% Public Companies and
Individual Investors